Abstract
Lymphoma is the sixth most common cause of cancer death in any individual person in the United States and there are over 50 recognized individual lymphoma pathologic entities. Even within relatively common entities such as diffuse large B-cell lymphoma, there are subgroups now defined by gene expression signatures and other genomic markers. Advances in our understanding of the genomic underpinnings of these diseases have led the design of novel therapeutic strategies that have begun to change the outcome for patients that cannot be cured with standard therapies. This chapter reviews our current understanding of the genomic alterations in the most common lymphoma subtypes and discusses recent approaches in precision medicine for lymphomas.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
